The Manila Times

FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare ...
The Manila Times

Lottery Defeated 2026: AI Accuracy Claims Examined, Pricing Verified, and What Consumers Should Confirm Before Buying

An informational consumer overview of Lottery Defeated software in 2026, analyzing the platform's AI prediction claims, Smart Pick algorithm language, pricing structure, refund policy, and what prospe ...

Ascendis Pharma: FDA Approves Once-Weekly YUVIWEL (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pedia ...
The Lancet

An international modified Delphi study to prioritise levels of evidence and outcomes to appraise radiotherapy innovation in the ESTRO Value-Based Radiation Oncology framework

This international Delphi study, led by the European Society of Radiation Oncology as part of their Value-Based Radiation Oncology programme, brought together key experts from the radiation oncology ...